| abstract |
The present invention relates to an immune modulator having a novel structure, and an immunologic adjuvant composition containing the same and, more specifically, to an modulator, which is a lipopolysaccharide (LPS) analog having reduced toxicity, and a use thereof. The immune modulator of the present invention exhibits immune enhancement effects by having excellent innate immunity and ability to induce an adaptive immune response to a specific pathogen, and is very safe by having low toxicity. In addition, a vaccine containing the immune modulator of the present invention contains both an immune modulator and an alum, thereby improving immune enhancement effects compared with when using only the immune modulator. |